Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse

Inclusion Criteria: Patients aged > 18 Histologically proven diagnosis of cancer of the ovary, the fallopian tube or peritoneum Peritoneal and/or nodes and/or visceral metastases Disease in progression under treatment or within 6 months after a first or second platinum-based line A period of 3 weeks between last chemotherapy and inclusion Measurable disease (Response Evaluation Criteria in Solid Tumors [RECIST] criteria) or cancer antigen (CA) 125 assessable disease (Gynecologic Cancer Intergroup [GCIG] criteria) ECOG performance status < 2 Life expectancy of at least 12 weeks Exclusion Criteria: Previously received weekly administration of paclitaxel chemotherapy Involved in a trial within the last 30 days Previously received a bone marrow autogreffe or irradiation of the abdomen within 5 years, due to intensive chemotherapy Prior diagnosis of malignancy History of ischemic cardiopathy, congestive heart failure (New York Heart Association [NYHA] > 2), arrhythmia, hypertension, or significant valvulopathy Pre-existing motor or sensory neurologic pathology or symptoms National Cancer Institute (NCI) - Common Terminology Criteria for Adverse Events (CTCAE) grade > 2 Bone marrow, renal, or hepatic insufficiency Severe active infection or occlusive or sub-occlusive disease History of symptomatic brain metastases Fertile women not using adequate contraceptive methods Pregnant or breast feeding women Hypersensitivity to compounds chemically related to paclitaxel, topotecan, or carboplatin